Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of “Buy” by Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has received an average rating of “Buy” from the seventeen analysts that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, fourteen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $284.00.

A number of research firms have weighed in on ASND. Barclays started coverage on Ascendis Pharma A/S in a research report on Tuesday, January 27th. They set an “overweight” rating and a $342.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Ascendis Pharma A/S in a report on Wednesday, November 26th. Morgan Stanley restated an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 21st. Finally, TD Cowen restated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, January 7th.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the business. Advisory Services Network LLC purchased a new position in Ascendis Pharma A/S in the third quarter worth $26,000. Leonteq Securities AG purchased a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at about $36,000. Global Retirement Partners LLC lifted its stake in shares of Ascendis Pharma A/S by 111.9% in the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the period. GW&K Investment Management LLC boosted its holdings in Ascendis Pharma A/S by 75.2% during the fourth quarter. GW&K Investment Management LLC now owns 226 shares of the biotechnology company’s stock worth $48,000 after buying an additional 97 shares in the last quarter. Finally, Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after buying an additional 83 shares during the period.

Ascendis Pharma A/S News Roundup

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: Strong revenue / product momentum: Ascendis reported Q4 revenue of $290.3M (above consensus) and highlighted robust YORVIPATH sales and growth momentum on the earnings call. This supports the company’s commercial trajectory. Read More.
• Positive Sentiment: Analyst upgrade / higher price target: Wedbush raised its price target from $240 to $273 and maintained an Outperform rating, implying ~25% upside from current levels and signaling analyst confidence in longer-term upside. Read More.
• Neutral Sentiment: Full earnings disclosure / transcripts available: Multiple transcripts and call highlights (TipRanks, Seeking Alpha, Yahoo) provide detail on guidance, commercialization cadence and pipeline positioning — useful for investors doing deeper due diligence but not immediate catalysts. Read More. • Read More.
• Neutral Sentiment: Short interest data shows no meaningful change (reported as zero in recent filings), so short-position flow does not appear to be a driving factor today. (Data items reported by market trackers.)
• Negative Sentiment: Big EPS miss: Ascendis reported GAAP EPS of ($0.64) vs. consensus $0.13 — a material miss that weighs on near-term sentiment despite revenue strength. Investors often punish earnings misses even when sales are growing. Read More.
• Negative Sentiment: Competitive risk in achondroplasia: Broader sector news (BridgeBio moves) has shifted the competitive landscape for achondroplasia treatments, pressuring peers including Ascendis and BioMarin. That dynamic is a headline-driven negative for the stock. Read More.
• Negative Sentiment: Conflicting coverage on revenue vs. estimates: Some outlets reported the quarter missed revenue expectations despite strong YORVIPATH uptake, adding short-term noise and uncertainty around street estimates. Read More.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $218.10 on Friday. The firm’s fifty day moving average is $214.64 and its two-hundred day moving average is $204.49. Ascendis Pharma A/S has a one year low of $124.06 and a one year high of $242.00. The firm has a market cap of $13.52 billion, a PE ratio of -49.57 and a beta of 0.44.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.76). The company had revenue of $250.71 million during the quarter, compared to analysts’ expectations of $246.91 million. Research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.